KSQ Therapeutics
MA - Lexington
Biotechnology1 H-1B visas (FY2023)Focus: CRISPR-based drug discovery
KSQ Therapeutics is a life sciences company focused on CRISPR-based drug discovery.
Gene Therapy
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$350M
Open Jobs
0
Pipeline & Clinical Trials
Cyclophosphamide
Select Advanced Solid TumorsClinical Trials (1)
NCT06598371A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2KSQ-001EX
Advanced Solid TumorClinical Trials (1)
NCT06237881A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Phase 1/2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2018
Portfolio: 2 clinical trials
H-1B (2023): 1 approval
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub